NCT05269940CompletedPhase 1

A Phase I/II Study Evaluating ZX-101A in Patients with Relapsed/Refractory Hematological Malignancies

Nanjing Zenshine Pharmaceuticals3 sites in 1 country40 target enrollmentStarted: February 17, 2022Last updated: November 13, 2024

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 1
Status: Completed
Sponsor
Enrollment: 40
Locations: 3
Primary Endpoint: Defining the RP2D of ZX-101A

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

ZX-101A-202 is a Phase I, open-label, multicenter study, a single-agent dose-escalation and dose-expansion study of ZX-101A. It is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacokinetics, efficacy and antitumor activity of ZX-101A in patients with relapsed/refractory hematological malignancies.

Detailed Description

Phase I includes two parts: dose escalation and dose expansion. It's mainly to explore the safety and tolerability of ZX-101A in patients with relapsed/ refractory hematological malignancies [Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL), indolent NHL, and other NHL subtypes], and to determine RP2D.

Part 1. ZX-101A dose escalation
Part 2. ZX-101A dose expansion in two specific types of lymphoma, i.e. PTCL /CTCL or one B-iNHL.

Study Design

Study Type: Interventional
Allocation: Non Randomized
Intervention Model: Sequential
Primary Purpose: Treatment
Masking: None

Eligibility Criteria

Ages: 18 Years to — (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•Males and females who are ≥ 18 years old
•Minimum life expectancy ≥ 3 months (determined by investigator assessment)
•Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
•Histopathological and cytological confirmed diagnosis of hematological malignancies.
•Phase I dose expansion and phase II studies require at least 1 measurable lesion, including cutaneous T-cell lymphoma [CTCL] without evidence of skin involvement.
•Acceptable bone marrow function.
•Acceptable organ function: creatinine clearance ≥ 60 mL/min calculated according to institutional standard practice assessment (according to the Cockcroft-Gault formula) for kidney function; AST and ALT ≤ 2.5 x upper limit of normal (ULN) (AST and ALT ≤ 4 x ULN in subjects with liver involvement); total bilirubin ≤ 1.5 x ULN (total bilirubin ≤ 3 in subjects with Gilbert syndrome ×ULN) for liver function.
•No transfusion or cytokine support for ≥ 2 weeks before first dosing.
•Ability to swallow oral medication.
•Negative serum pregnancy test in women of childbearing potential at screening.
•Females of childbearing potential and males with female partners of childbearing potential must agree to use effective contraception during the study period and for 6 months (females) or 3 months (males) after the last dose of ZX-101A.
•Men must agree to no sperm donation during the study and for 3 months after the last dose of ZX-101A.
•Understands the requirements of the study, is willing to comply with all study procedures and signed the IRB-approved informed consent.

Exclusion Criteria

•Previous use of PI3K δ/γ dual inhibitors
•Received approved anti-cancer drugs within 28 days (42 days for nitrosoureas) or 5 half-lives, whichever is longer.
•Radiation treatment within 2 weeks prior to first dose of study treatment.
•Received investigational study drug within 28 days (or 5 half-lives, whichever is longer).
•Received organ transplantation in the past (hematopoietic stem cell transplantation in the past is allowed).
•Major surgery within 28 days prior to the first dose of study drug
•Has not recovered from adverse events from prior anti-cancer treatment (with exception of alopecia).
•Concurrent participation in another therapeutic treatment trial.
•Those who have been vaccinated with live vaccines or live attenuated vaccines within 30 days before the first administration, and seasonal influenza vaccines without live viruses are allowed.
•Received warfarin or factor Xa inhibitor within 5 half-lives before the first dose of study drug.
•With central nervous system (CNS) involvement or active leptomeningeal disease.
•History of other malignancy within the past 5 years, unless cured by surgery and sustained disease-free survival.
•CLL with Richter transformation.
•Active autoimmune hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP)
•Chronic immunosuppression conditions.
•QTcF interval > 480 msec; echocardiographic detection of left ventricular ejection fraction < 45%.
•Uncontrolled systemic diseases, including myocardial infarction or bypass, stent surgery, or other heart disease, in the judgement of the investigator, inappropriate for enrollment.
•Active uncontrolled infection within 14 days before first dosing.
•Active infection of Hepatitis B virus or hepatitis C virus; history of HIV infection.
•History of drug-induced liver injury, chronic active hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, persistent extrahepatic obstruction due to gallstones, cirrhosis or portal vein history of hypertension.
•History of interstitial lung disease, hypersensitivity pneumonitis, pulmonary fibrosis, radiation pneumonitis and severe pulmonary function impairment, or other pulmonary diseases that significantly affect the safety or compliance of patients after being evaluated and included by the investigator.
•Gastrointestinal dysfunction, including motility or malabsorption syndromes or inflammatory bowel disease which could limit absorption of study drug.
•Any concurrent uncontrolled illness, including mental illness or substance abuse.